Filing Flows › Gilead Sciences (GILD) › Total HIV revenue
Gilead Sciences (GILD) Total HIV revenue by quarter
Gilead Sciences' Total HIV revenue was $6.3B in Q3 2026 (third quarter 2026), +10% from Q2 2026. Over the last 6 quarters it ranged from $4.6B (Q1 2025) to $6.3B (Q3 2026).
| Quarter | Total HIV revenue | Q/Q | Y/Y |
|---|---|---|---|
| Q3 2026 | $6.3B | +10% | — |
| Q2 2026 | $5.7B | +13% | +12% |
| Q1 2026 | $5.0B | -13% | +10% |
| Q4 2025 | $5.8B | +14% | — |
| Q2 2025 | $5.1B | +11% | — |
| Q1 2025 | $4.6B | — | — |
Q3 2026 at a glance
Gilead Sciences, Q3 2026: revenue $8.3B (+7% year over year), operating margin 41.7%, net earnings $2.4B, operating cash flow $5.0B. The chart follows the revenue to costs, profit and cash.
Questions
What is Gilead Sciences' Total HIV revenue?
Gilead Sciences' Total HIV revenue was $6.3B in Q3 2026 (third quarter 2026), +10% from Q2 2026.
How has Gilead Sciences' Total HIV revenue changed?
Over the last 6 quarters it ranged from $4.6B (Q1 2025) to $6.3B (Q3 2026).